Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment

This review discusses the use of botulinum toxin for hair and scalp disorders and reports mixed findings, with most studies showing mild or non-significant effects on hair growth.

This study explored whether using topical minoxidil can temporarily increase hair shedding, but results are not reported.

This randomized, double-blind, placebo-controlled phase III trial found that a 24-week treatment with topical finasteride significantly increased hair growth and was well-tolerated in Chinese men with androgenetic alopecia compared to placebo.

This study analyzed adverse event reports from the FDA Adverse Event Reporting System and identified new side effects of topical minoxidil, such as application site acne and cysts, which are not well-documented on product labels, suggesting a need for updated safety information.

In this systematic review, the researchers observed that topical caffeine preparations appear safe and effective against hair loss, but most studies had low-quality evidence due to design flaws, indicating the need for better-designed trials before drawing definitive conclusions.

DMG-Na may help reduce hair loss and improve hair growth, but more research is needed.

This review highlights the critical role of mitochondrial dysfunction in hair loss, particularly androgenetic alopecia, and explores potential therapies targeting mitochondrial pathways to improve hair health, underscoring the need for further research in this area.

This study suggests that androgenetic alopecia may increase the risk of developing depression, but depression does not significantly contribute to the onset of androgenetic alopecia.

In this review, the authors discuss caffeine's potential mechanisms and benefits as a hair loss treatment, noting its possible effectiveness and safety, though they caution that existing studies often have significant design flaws.

This study observed that CXCL12 is highly co-expressed with androgen receptors in human hair follicle cells, and its inhibition via antibodies increased hair length, suggesting a potential treatment strategy for androgenic alopecia.

Results of the effect and safety of a gummy supplement with B vitamins, zinc, and botanicals on hair growth and quality in women with thinning hair are not reported in this abstract.

This review found that deficiencies or imbalances in micronutrients like vitamin B, vitamin D, iron, and zinc may play a role in androgenetic alopecia and could be modifiable risk factors for prevention and treatment, though evidence varies.

In this meta-analysis, researchers found that oral and topical minoxidil treatments for androgenetic alopecia had similar efficacy in improving hair density and diameter, but oral minoxidil resulted in a higher incidence of hypertrichosis compared to topical use.

This study found that a combination of topical finasteride 0.25% with minoxidil 5% was more effective than using topical minoxidil 5% alone for treating male pattern androgenic alopecia over a 12-week period.

This review discusses current and emerging therapies for androgenetic alopecia, emphasizing regenerative treatments and nanotechnology advancements, but it reports no new clinical results.

This review concludes that low-level laser therapy is the most supported physical treatment for androgenetic alopecia, but other therapies like nonablative laser treatments and combinations including PEMF may also be promising.

This review discusses the increasing prevalence of alopecia in younger populations and outlines the need for better understanding its pathogenesis to develop effective treatments. It also examines current FDA-approved drugs and emerging small molecule compounds with potential anti-alopecia effects.

This study reviewed the publication trends and key findings on alternative therapies for androgenetic alopecia, highlighting the increasing research interest in dutasteride and nontopical minoxidil, while noting a lack of high-quality trials for nontopical minoxidil formulations.

In this study, researchers found that topical treatment with adenosine improved hair growth and thickness by significantly increasing hair density and thickness after four months in vivo, with results comparable to minoxidil, potentially due to adenosine's anti-androgenic effects.

Topical minoxidil effectively stimulates hair growth in men with hair loss.

In this self-controlled comparative study of 16 women with Female Pattern Hair Loss, MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced cases compared to standard Minoxidil treatment, though overall effectiveness was similar.

In this study, researchers found that bicalutamide was more effective and had a better safety profile than spironolactone for treating female-pattern hair loss in women aged 18 to 50, based on the Sinclair scale and photographic assessments after 24 weeks of treatment.

This systematic review concluded that various treatments, such as topical minoxidil, oral finasteride, and hair transplantation, effectively promote hair growth in androgenic alopecia, emphasizing the benefits of a personalized, multifaceted treatment approach.

This study found no significant laboratory differences between Caucasian adults with non-cicatricial alopecia and healthy controls, but reported that affected individuals were significantly younger, suggesting that lifestyle and diet might contribute to early hair loss risk.

This review examined clinical studies on topical melatonin for skin protection and found strong evidence that it effectively prevents skin damage from radiation, but noted limited clear evidence for its anti-aging and hair growth benefits due to study design limitations and combined treatments.

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

Taking medication for hair loss might cause sexual problems.

This review discusses the potential strategy of continuing topical minoxidil when starting low dose oral minoxidil to mitigate initial hair shedding in alopecia, but reports no new clinical results.

This study found that oral isotretinoin significantly reduced symptoms in nearly 90% of patients with frontal fibrosing alopecia, affecting both facial papules and hair loss.

This review outlines the functional anatomy, pathology, and molecular mechanisms of androgenetic alopecia, emphasizing the need for multi-omics approaches to better understand this condition's biology.

This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.

This study found that patients with non-scarring alopecia, such as androgenetic alopecia and female pattern hair loss, have lower serum levels of 25-hydroxyvitamin D and a higher incidence of vitamin D deficiency compared to healthy controls.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

This review discusses botulinum toxin A as a treatment for various types of hair loss and reports no clinical results; the authors emphasize the need for comprehensive evaluations and further research.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

This study found that combining minoxidil and spironolactone was more effective for hair density and severity of hair loss in women with androgenic alopecia compared to minoxidil and finasteride, with no serious adverse effects reported.

This study found that while both topical cetirizine and minoxidil improved female pattern hair loss, minoxidil was significantly more effective in increasing hair density.

This study found that minoxidil may treat androgenetic alopecia by affecting hormonal and enzymatic pathways, identifying new targets CYP17A1 and CYP19A1 and demonstrating its inhibition of androgenic receptors.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This study observed that both finasteride and dutasteride significantly decreased dihydrotestosterone concentrations in hair, with dutasteride showing the greatest reduction.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

This article reviews treatment options for female-pattern hair loss, noting the limited evidence for most therapies and emphasizing that topical minoxidil remains the only well-supported option despite a significant non-response rate.

This systematic review concluded that 5 mg of oral finasteride per day could be an effective and safe treatment for female pattern hair loss in normoandrogenic women, particularly when combined with other medications.

This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.

This study identified CXXC5 as a key mediator of hair loss induced by PGD2 and DHT via suppression of the Wnt/β-catenin pathway, with implications for potential therapeutic targets.

This review discusses the roles of prostaglandins in hair loss and highlights their potential as targets for new alopecia treatments, but reports no new clinical findings.

This retrospective study found that hair loss occurred in some isotretinoin patients, with those experiencing hair loss being older and having longer treatment durations and higher doses compared to controls.

This study found that adenosine promotes hair growth by stimulating the Wnt/β-catenin pathway in cultured human dermal papilla cells through activation of the adenosine receptor.

This review found that topical finasteride has similar efficacy to oral finasteride in treating male and female pattern hair loss, with fewer systemic side effects, mainly causing localized scalp reactions like irritation and erythema.

In this study, a novel topical bimatoprost formulation (BIM-TF#5) significantly enhanced hair regrowth and increased dermal drug deposition in both human skin models and an androgenic alopecia mouse model compared to previous preparations.

This study found that androgen receptor signaling is linked to blood vessel regression in the dermal papilla of balding scalp, contributing to hair follicle miniaturization in androgenetic alopecia.

This study found that combining oral vitamin D with topical minoxidil improved female pattern hair loss more effectively than either treatment alone.

This review discusses the potential link between low serum vitamin D levels and androgenetic alopecia and reports that vitamin D might be useful for diagnosis and treatment, but no new clinical results are included.

This study found that in the treatment of androgenetic alopecia, combination therapies involving topical and systemic treatments with adjunctive therapy demonstrated the highest efficacy in improving hair density and diameter compared to placebo, based on a network meta-analysis of 49 randomized controlled trials.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This article poses the question of whether Janus kinase (JAK) inhibitors are beneficial for treating androgenic alopecia, but it does not provide results or conclusions from any study.

This article's abstract is unavailable and does not provide any new results; readers are advised to contact the corresponding author for more information.

This study found that 3D-cultured dermal papilla cells more accurately mimic in vivo conditions compared to 2D cultures, enhancing our understanding of molecular mechanisms in androgen-induced alopecia.

This systematic review of five studies found that intradermal and intramuscular botulinum toxin injections showed promising hair growth outcomes for men with androgenic alopecia, but emphasizes caution due to a lack of control groups and small sample sizes.

This review discusses the dermatological applications of botulinum toxin, including off-label uses for various skin conditions, and calls for a better understanding of underlying muscular anatomy for effective clinical practice.

This review found that oral spironolactone is an effective and well-tolerated treatment for androgenic alopecia in women, especially when used with topical minoxidil, with generally minimal side effects reported.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.

This study found that adding 10 mg/day of biotin to isotretinoin treatment for acne improved hair growth and maintained skin hydration, potentially reducing isotretinoin's mucocutaneous side effects.

This review concluded that botulinum toxins have various potential off-label uses for dermatological conditions, but further research is needed to fully establish their efficacy and safety in these applications.

This study observed that fibrosis occurs in the bulge region of hair follicles affected by androgenetic alopecia and is correlated with the hair miniaturization process.

This study found that increased levels of PGD2 and prostacyclin and decreased levels of PGE2 and PGF2α were associated with baldness in androgenetic alopecia, suggesting potential targets for treatment.

This study found that women with telogen effluvium had significantly lower levels of hemoglobin, ferritin, and vitamin B12 compared to other groups and men.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

This consensus concluded that oral isotretinoin is highly effective for treating acne and some off-label conditions, with common adverse events being manageable and rare serious risks not contraindicating use.

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This article discusses the potential for topical caffeine as a natural alternative for treating androgenetic alopecia due to its ability to penetrate skin, but it reports no new clinical findings.

This systematic review suggests that topical ketoconazole may improve hair regrowth and thickness in both animal and human studies for androgenetic alopecia, but further randomized controlled trials are needed.

This article addresses the mechanisms of androgenic alopecia and seeks to clarify misconceptions, but it reports no new empirical findings and calls for further controlled studies.

This study found that vascular endothelial growth factor may protect hair follicle stem cells from androgen-induced apoptosis in androgenic alopecia patients via the PI3K/Akt pathway.

This study observed that hair follicles in hair loss patients had increased levels of Propionibacterium acnes, potentially linked to elevated immune response gene expression in miniaturized hair follicles.

Small Botox dose effectively treats hair loss in Chinese men.

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.

This review evaluates dihydrotestosterone's role in androgenic alopecia and proposes a model suggesting that chronic scalp tension and inflammation contribute to hair follicle miniaturization, identifying fibrosis, calcification, and tension as treatment targets.

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

This study found that topical adenosine significantly increased the ratio of thick hairs and contributed to global improvement in Japanese men with androgenetic alopecia compared to niacinamide, with no observed adverse events.

This study found that in androgenic alopecia, the arrector pili muscle degenerates and is replaced by fat, unlike in normal skin or telogen effluvium.

This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.

In this study, topical adenosine 0.75% and minoxidil 5% had similar recovery rates for androgenetic alopecia, but patients reported higher satisfaction with adenosine due to quicker hair loss prevention and new hair appearance.

This study found that bimatoprost stimulated hair growth in both human scalp follicle cultures and mouse pelage in vivo, suggesting it might offer a promising treatment for scalp alopecias.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.

The study reported that combining the Follicular Closing Technique with the Franz diffusion cell is a valuable method for investigating follicular caffeine penetration in vitro, though kinetics differ from in vivo results.

This study found that caffeine can stimulate hair growth in vitro and counteract testosterone-induced growth suppression in hair follicles from male AGA patients.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.